ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ELUT vs ESLA // EV/EBITDA & P/E VALUATION

Elutia Inc. (Class A) (NASDAQ) VS. Estrella Immunopharma Inc. (NASDAQ) • 15-METRIC TALLY: ELUT 3 — ESLA 0
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ELUT VS. ESLA) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ELUT ESLA SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 53.70% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield — -5.63% — TIE /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin 68.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 1/9 +3.00 ELUT /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 53.5 51.5 +2.01 ELUT /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $36.0M $31.7M $4.3M ELUT /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ELUT REV ESLA REV ELUT GROSS % ESLA GROSS % ELUT FCF ESLA FCF
FY 2025 $12.3M $0 53.7% — -$46.7M -$1.8M
FY 2024 $14.5M $0 46.4% — -$23.3M -$16.1M
FY 2023 $0 $0 — — -$21.8M -$1.3M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ELUT // BETA —
ESLA // BETA —